Endothelin Receptor Antagonists for Kidney Protection: Lessons from the SONAR Trial.
作者信息
Heerspink Hiddo J L, de Zeeuw Dick
机构信息
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
出版信息
Clin J Am Soc Nephrol. 2022 Jun;17(6):908-910. doi: 10.2215/CJN.00560122. Epub 2022 Apr 28.
Abstract
摘要
相似文献
1
Endothelin Receptor Antagonists for Kidney Protection: Lessons from the SONAR Trial.
Clin J Am Soc Nephrol. 2022 Jun;17(6):908-910. doi: 10.2215/CJN.00560122. Epub 2022 Apr 28.
2
Atrasentan for the treatment of diabetic nephropathy.
Expert Opin Investig Drugs. 2017 Jun;26(6):741-750. doi: 10.1080/13543784.2017.1325872.
3
Endothelin receptor antagonists in clinical research--lessons learned from preclinical and clinical kidney studies.
Life Sci. 2014 Nov 24;118(2):141-8. doi: 10.1016/j.lfs.2014.02.025. Epub 2014 Mar 4.
4
Endothelin-receptor antagonists for diabetic nephropathy: A meta-analysis.
Nephrology (Carlton). 2015 Jul;20(7):459-66. doi: 10.1111/nep.12442.
5
Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.
Curr Opin Nephrol Hypertens. 2021 Jul 1;30(4):456-465. doi: 10.1097/MNH.0000000000000716.
6
[Pharmacological and clinical profile of a novel dual endothelin receptor antagonist, macitentan (Opsumit)].
Nihon Yakurigaku Zasshi. 2017;149(1):49-58. doi: 10.1254/fpj.149.49.
7
Endothelin antagonists in clinical trials: lessons learned.
Contrib Nephrol. 2011;172:255-260. doi: 10.1159/000328859. Epub 2011 Aug 30.
8
Therapeutic transformation for diabetic kidney disease.
Kidney Int. 2021 Feb;99(2):301-303. doi: 10.1016/j.kint.2020.10.003.
9
Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
Br J Clin Pharmacol. 2013 Oct;76(4):573-9. doi: 10.1111/bcp.12064.
10
Update on Endothelin Receptor Antagonists in Hypertension.
Curr Hypertens Rep. 2018 May 19;20(6):51. doi: 10.1007/s11906-018-0848-0.
引用本文的文献
1
Endothelin-1 signaling in the kidney: recent advances and remaining gaps.
Am J Physiol Renal Physiol. 2025 Jun 1;328(6):F815-F827. doi: 10.1152/ajprenal.00304.2024. Epub 2025 Apr 24.
2
Research trends and performance of endothelin A receptor antagonist in kidney care: a bibliometric analysis.
Ren Fail. 2025 Dec;47(1):2487212. doi: 10.1080/0886022X.2025.2487212. Epub 2025 Apr 11.
3
Effects of combining zibotentan and dapagliflozins on chronic kidney disease: an innovative frontier.
Int Urol Nephrol. 2025 May;57(5):1657-1658. doi: 10.1007/s11255-024-04310-3. Epub 2024 Dec 4.
4
Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease.
Clin Kidney J. 2024 Mar 19;17(4):sfae072. doi: 10.1093/ckj/sfae072. eCollection 2024 Apr.
5
Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy.
Nephrol Dial Transplant. 2024 Aug 30;39(9):1494-1503. doi: 10.1093/ndt/gfae021.
6
Central role of podocytes in mediating cellular cross talk in glomerular health and disease.
Am J Physiol Renal Physiol. 2024 Mar 1;326(3):F313-F325. doi: 10.1152/ajprenal.00328.2023. Epub 2024 Jan 11.
7
Treatment and practical considerations of diabetic kidney disease.
Front Med (Lausanne). 2023 Dec 1;10:1264497. doi: 10.3389/fmed.2023.1264497. eCollection 2023.
8
Endothelin System in Hypertension and Chronic Kidney Disease.
Hypertension. 2024 Apr;81(4):691-701. doi: 10.1161/HYPERTENSIONAHA.123.21716. Epub 2023 Dec 7.
9
Add-on Rehmannia-6-Based Chinese Medicine in Type 2 Diabetes and CKD: A Multicenter Randomized Controlled Trial.
Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1163-1174. doi: 10.2215/CJN.0000000000000199. Epub 2023 Jun 12.
10
Early diabetic kidney disease: Focus on the glycocalyx.
World J Diabetes. 2023 May 15;14(5):460-480. doi: 10.4239/wjd.v14.i5.460.
Zotero 插件